Cybin (CYBN) – Investment Analysts’ Recent Ratings Updates

Cybin (NYSEAMERICAN: CYBN) has recently received a number of price target changes and ratings updates:

• 9/1/2023 – Cybin had its “buy” rating reaffirmed by analysts at Canaccord Genuity Group Inc.. They now have a $5.00 price target on the stock.
• 8/30/2023 – Cybin had its “outperform” rating reaffirmed by analysts at Oppenheimer Holdings Inc.. They now have a $4.00 price target on the stock.
• 8/29/2023 – Cybin had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $3.00 price target on the stock.
• 8/29/2023 – Cybin had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
• 8/22/2023 – Cybin had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $3.00 price target on the stock.
• 8/15/2023 – Cybin had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.

Cybin Stock Performance

Shares of NYSEAMERICAN:CYBN traded down $0.02 during trading on Tuesday, reaching $0.44. 8,184,729 shares of the company were exchanged, compared to its average volume of 2,164,423. The firm has a market cap of $89.03 million, a PE ratio of -2.34 and a beta of 1.52. Cybin Inc. has a 12-month low of $0.21 and a 12-month high of $0.71.

Cybin (NYSEAMERICAN:CYBN) last released its quarterly earnings data on Tuesday, June 27th. The company reported ($0.05) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.05). Equities research analysts predict that Cybin Inc. will post -0.18 EPS for the current fiscal year.

Cybin Inc, a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation.